Thumbnail Image
Publication

ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation

Abou-Alfa, GK
; 
Mercade, TM
; 
Javle, M
; 
Kelley, RK
; 
Lubner, S
; 
Adeva, J
; 
Cleary, JM
; 
Catenacci, DV
; 
Borad, MJ
; 
Bridgewater, JA
... show 10 more
Citations
Altmetric:
Abstract
Authors
Abou-Alfa, GK
Mercade, TM
Javle, M
Kelley, RK
Lubner, S
Adeva, J
Cleary, JM
Catenacci, DV
Borad, MJ
Bridgewater, JA
Harris, WP
Murphy, AG
Oh, DY
Whisenant, J
Wu, B
Jiang, L
Gliser, C
Pandya, SS
Valle, Juan W
Zhu, AX
Affiliation
Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
Description
Date
2019
Publisher
Collections
All Christie Publications
Show all metadata
Files
Thumbnail Image
From UNPAYWALL. Conference abstract
Adobe PDF, 101.31 KB
Keywords
Type
Meetings and Proceedings
Citation
Abou-Alfa GK, Macarulla Mercade T, Javle M, Kelley RK, Lubner S, Adeva J, et al. LBA10_PRClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Annals of Oncology. 2019;30(Supplement_5):872.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/622597
Embedded videos